Eyepoint Pharmaceuticals (NASDAQ:EYPT) Receives “Neutral” Rating from JPMorgan Chase & Co.

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “neutral” rating reiterated by equities researchers at JPMorgan Chase & Co. in a research note issued on Monday,Benzinga reports.

EYPT has been the subject of a number of other research reports. Chardan Capital reaffirmed a “buy” rating and issued a $65.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Monday. Cantor Fitzgerald lowered shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 target price for the company. Royal Bank Of Canada cut their price target on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, HC Wainwright reduced their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eyepoint Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Eyepoint Pharmaceuticals Price Performance

NASDAQ:EYPT traded down $10.12 during trading hours on Monday, reaching $4.63. 34,567,836 shares of the company were exchanged, compared to its average volume of 1,510,330. The business has a 50 day moving average of $13.23 and a 200 day moving average of $13.70. Eyepoint Pharmaceuticals has a 1-year low of $3.95 and a 1-year high of $19.11. The company has a market capitalization of $399.58 million, a P/E ratio of -1.22 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. As a group, equities research analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its holdings in Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares during the last quarter. RWC Asset Management LLP raised its holdings in Eyepoint Pharmaceuticals by 6.4% during the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after purchasing an additional 1,040 shares during the last quarter. MCF Advisors LLC raised its holdings in Eyepoint Pharmaceuticals by 8.3% during the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after purchasing an additional 1,149 shares during the last quarter. Raymond James Financial Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after purchasing an additional 1,177 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.